clinical trial · NCT06745323
A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC
Amgen·phase2·active not recruiting·n = 252
Small Cell Lung Cancer (SCLC)Tarlatamab
brief summary
The primary objective of this study is to describe the antitumor activity of tarlatamab in participants with small cell lung cancer (SCLC).
started
Feb 26, 2025
primary completion
Feb 9, 2029
completion
Feb 9, 2029
last updated
Mar 3, 2026
official title
A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With Small Cell Lung Cancer (SCLC) (DeLLphi-309)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol